Veracyte (VCYT) EBIAT (2016 - 2025)
Veracyte (VCYT) has disclosed EBIAT for 14 consecutive years, with $41.1 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 704.79% to $41.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.4 million through Dec 2025, up 174.89% year-over-year, with the annual reading at $66.4 million for FY2025, 174.89% up from the prior year.
- EBIAT hit $41.1 million in Q4 2025 for Veracyte, up from $19.1 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $41.1 million in Q4 2025 to a low of -$41.9 million in Q1 2021.
- Historically, EBIAT has averaged -$4.8 million across 5 years, with a median of -$8.2 million in 2023.
- Biggest five-year swings in EBIAT: tumbled 636.03% in 2023 and later surged 704.79% in 2025.
- Year by year, EBIAT stood at -$10.5 million in 2021, then skyrocketed by 63.49% to -$3.8 million in 2022, then crashed by 636.03% to -$28.3 million in 2023, then soared by 118.07% to $5.1 million in 2024, then surged by 704.79% to $41.1 million in 2025.
- Business Quant data shows EBIAT for VCYT at $41.1 million in Q4 2025, $19.1 million in Q3 2025, and -$980000.0 in Q2 2025.